clinical trial · NCT07471230
Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism
Biocells Medical·phase2·not yet recruiting·n = 120
Parkinsonism or Parkinson's Disease NosParkinsonism in Diseases Classified ElsewhereIntrathecal (IT)Intravenous
brief summary
This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism. The study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.
started
Nov 23, 2026
primary completion
Nov 23, 2028
completion
Nov 23, 2029
last updated
Mar 13, 2026
official title
Phase II Randomized Controlled Trial Evaluating Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol